Q4 Earnings Forecast for Moderna Issued By Leerink Partnrs

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of Moderna in a research note issued on Monday, January 13th. Leerink Partnrs analyst M. Foroohar anticipates that the company will post earnings per share of ($2.54) for the quarter. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share. Leerink Partnrs also issued estimates for Moderna’s FY2028 earnings at ($2.70) EPS and FY2029 earnings at ($0.07) EPS.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.39) earnings per share.

Several other analysts also recently commented on MRNA. Berenberg Bank began coverage on Moderna in a research note on Tuesday, November 19th. They issued a “hold” rating and a $42.00 price objective for the company. Wolfe Research began coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. JPMorgan Chase & Co. cut their price target on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a report on Tuesday, November 26th. Finally, Barclays dropped their target price on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $78.83.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $34.46 on Wednesday. The stock has a market cap of $13.26 billion, a price-to-earnings ratio of -5.92 and a beta of 1.60. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna has a fifty-two week low of $31.94 and a fifty-two week high of $170.47. The firm’s 50-day simple moving average is $41.78 and its 200 day simple moving average is $67.79.

Insider Buying and Selling

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC bought a new position in Moderna in the 2nd quarter valued at $26,000. Plato Investment Management Ltd raised its holdings in shares of Moderna by 230.4% in the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after acquiring an additional 288 shares in the last quarter. Blue Trust Inc. boosted its position in shares of Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after acquiring an additional 574 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Rakuten Securities Inc. increased its position in shares of Moderna by 477.3% in the third quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after purchasing an additional 778 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.